ES2797395T3 - Composiciones para el tratamiento del síndrome X frágil - Google Patents

Composiciones para el tratamiento del síndrome X frágil Download PDF

Info

Publication number
ES2797395T3
ES2797395T3 ES12735048T ES12735048T ES2797395T3 ES 2797395 T3 ES2797395 T3 ES 2797395T3 ES 12735048 T ES12735048 T ES 12735048T ES 12735048 T ES12735048 T ES 12735048T ES 2797395 T3 ES2797395 T3 ES 2797395T3
Authority
ES
Spain
Prior art keywords
mice
chloro
fxs
fmr1
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12735048T
Other languages
English (en)
Spanish (es)
Inventor
Sylvain Briault
Olivier Perche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Regional Dorleans
Centre National de la Recherche Scientifique
University of Orléans
Original Assignee
Centre Hospitalier Regional Dorleans
Centre National de la Recherche Scientifique
University of Orléans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Regional Dorleans, Centre National de la Recherche Scientifique, University of Orléans filed Critical Centre Hospitalier Regional Dorleans
Application granted granted Critical
Publication of ES2797395T3 publication Critical patent/ES2797395T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES12735048T 2011-06-27 2012-06-19 Composiciones para el tratamiento del síndrome X frágil Active ES2797395T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11171532A EP2540295A1 (en) 2011-06-27 2011-06-27 Compositions for the treatment of Fragile X syndrome
PCT/IB2012/053089 WO2013001412A1 (en) 2011-06-27 2012-06-19 Compositions for the treatment of fragile x syndrome

Publications (1)

Publication Number Publication Date
ES2797395T3 true ES2797395T3 (es) 2020-12-02

Family

ID=44840530

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12735048T Active ES2797395T3 (es) 2011-06-27 2012-06-19 Composiciones para el tratamiento del síndrome X frágil

Country Status (8)

Country Link
US (1) US10435366B2 (enExample)
EP (2) EP2540295A1 (enExample)
JP (1) JP6012726B2 (enExample)
DK (1) DK2723336T3 (enExample)
ES (1) ES2797395T3 (enExample)
PL (1) PL2723336T3 (enExample)
PT (1) PT2723336T (enExample)
WO (1) WO2013001412A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2540295A1 (en) * 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions for the treatment of Fragile X syndrome
AU2014233048B2 (en) * 2013-03-15 2019-01-03 The Children's Hospital Of Philadelphia Magnetoencephalography biomarkers of GABA-B agonist drug activity in autism spectrum disorders
US20180116983A1 (en) 2015-02-13 2018-05-03 Canbex Therapeutics Limited Compounds for treating disorders associated with bk channel modulation
AU2018225758A1 (en) 2017-02-24 2019-09-05 Ovid Therapeutics Inc. Methods of treating seizure disorders
WO2019126643A1 (en) 2017-12-22 2019-06-27 Massachusetts Institute Of Technology Compositions and methods for williams syndrome (ws) therapy
EP3912625A1 (en) * 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
WO2025233532A1 (en) 2024-05-10 2025-11-13 Les Laboratoires Servier Maxi-k potassium channel openers and therapeutic applications thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
US20020045566A1 (en) 2000-10-13 2002-04-18 Gribkoff Valentin K. Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
MXPA03007397A (es) * 2001-02-20 2003-12-04 Bristol Myers Squibb Co Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
HUP0400063A2 (hu) * 2001-02-20 2004-04-28 Bristol-Myers Squibb Company Fluor-oxo-indolszármazékok mint KCNQ káliumcsatorna modulátorok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
FR2857452B1 (fr) * 2003-07-11 2005-09-30 Univ Rabelais Francois Test de depistage de l'autisme, methode de selection de patients repondant audit test et utilisation des medicaments activateurs de canaux bkca pour le traitement de ladite maladie
DE102004053673A1 (de) * 2004-11-03 2006-05-04 Endress + Hauser Flowtec Ag Vorrichtung zur Bestimmung und/oder Überwachung des Volumen- und/oder Massendurchflusses eines Mediums
US20100247552A1 (en) 2006-11-10 2010-09-30 Massachusetts Institute Of Technology Pak modulators
WO2009000038A1 (en) * 2007-06-28 2008-12-31 Cnsbio Pty Ltd Combination methods and compositions for treatment of neuropathic pain
EP2540295A1 (en) * 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions for the treatment of Fragile X syndrome

Also Published As

Publication number Publication date
US20140221450A1 (en) 2014-08-07
EP2723336B1 (en) 2020-04-08
DK2723336T3 (da) 2020-06-29
WO2013001412A1 (en) 2013-01-03
US10435366B2 (en) 2019-10-08
JP6012726B2 (ja) 2016-10-25
PT2723336T (pt) 2020-07-14
EP2723336A1 (en) 2014-04-30
PL2723336T3 (pl) 2020-10-19
EP2540295A1 (en) 2013-01-02
JP2014518255A (ja) 2014-07-28

Similar Documents

Publication Publication Date Title
Popova et al. Neuronal and behavioral plasticity: The role of serotonin and BDNF systems tandem
Kinghorn et al. A Drosophila model of neuronopathic Gaucher disease demonstrates lysosomal-autophagic defects and altered mTOR signalling and is functionally rescued by rapamycin
Depoortère et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic
Xu et al. Identification of a glutamatergic claustrum-anterior cingulate cortex circuit for visceral pain processing
Meyer et al. Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling
US10435366B2 (en) Compositions for the treatment of Fragile X syndrome
Saadati et al. Serotonin depletion during the postnatal developmental period causes behavioral and cognitive alterations and decreases BDNF level in the brain of rats
Zhang et al. Cell type-specific NRBF2 orchestrates autophagic flux and adult hippocampal neurogenesis in chronic stress-induced depression
Marcinkiewcz et al. Sex-dependent modulation of anxiety and fear by 5-HT1A receptors in the bed nucleus of the stria terminalis
Gardier Mutant mouse models and antidepressant drug research: focus on serotonin and brain-derived neurotrophic factor
Paribello et al. Melatonin and aggressive behavior: A systematic review of the literature on preclinical and clinical evidence
Wu et al. Contribution of hippocampal 5-HT3 receptors in hippocampal autophagy and extinction of conditioned fear responses after a single prolonged stress exposure in rats
Hou et al. The involvement of oxytocin in the effects of chronic social defeat stress on emotional behaviours in adult female mandarin voles
Choi Potency of melatonin in living beings
Zou et al. Noradrenergic Locus Coeruleus‐CA3 Activation Alleviates Neuropathic Pain and Anxiety‐and Depression‐Like Behaviors by Suppressing Microglial Neuroinflammation in SNI Mice
Sharghi et al. Evaluating the effect of R-Baclofen and LP-211 on autistic behavior of the BTBR and Fmr1-KO mouse models
Pirmoradi et al. Resveratrol and 1, 25-dihydroxyvitamin D decrease Lingo-1 levels, and improve behavior in harmaline-induced essential tremor, suggesting potential therapeutic benefits
Zhang et al. TMEM175 downregulation participates in impairment of the autophagy related lysosomal dynamics following neonatal hypoxic‐ischemic brain injury
Norris et al. Mu opioid receptors gate the locus coeruleus pain generator
Xu et al. SERCA2 protects against cisplatin-induced damage of auditory cells: Possible relation with alleviation of ER stress
Rex et al. Neurotransmitter and behaviour: serotonin and anxiety
Xu et al. Modulation Of SUDEP By Central Serotonergic Cooperating with Noradrenergic Circuits: A Synergistic-Dependent Manner
Sabariego Navarro DISENTANGLING THE ROLE OF GABAERGIC HIPPOCAMPAL INTERNEURONS IN MEMORY DEFICITS IN DOWN SYNDROME
Vahid-Ansari Altered serotonin regulation in genetic and post-stroke models of anxiety and depression
Badimon Region-Specific Microglial Modulation of Neuronal Activity